CASI Pharmaceuticals, Inc. (CASI)

CASI Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	17.08	47.11	38.7	57.06	53.62
Short-Term Investments	13.69	4.23	9.87	9.31	0.63
Cash & Cash Equivalents	30.77	51.34	48.57	66.37	54.25
Cash Growth	-40.06%	5.69%	-26.82%	22.36%	-36.27%
Receivables	10.14	12.97	9.8	4.65	1.29
Inventory	15.88	6.14	1.91	1.36	4.54
Other Current Assets	2.56	2.98	1.69	1.65	4.64
Total Current Assets	59.34	73.42	61.97	74.03	64.72
Property, Plant & Equipment	11.63	13.23	21.82	10.76	9.69
Long-Term Investments	1.69	7.46	40.13	29.44	14.04
Goodwill and Intangibles	1.84	1.06	12.2	13.21	13.67
Other Long-Term Assets	0.77	1.06	2.18	0.3	0.5
Total Long-Term Assets	15.92	22.81	76.33	53.71	37.91
Total Assets	75.27	96.23	138.3	127.73	102.63
Accounts Payable	4.44	3.29	2.22	3.26	5.11
Deferred Revenue	0	0	2.83	2.35	0
Current Debt	0	0	0	1.29	0
Other Current Liabilities	12.29	13.72	8.14	1.07	2.83
Total Current Liabilities	16.73	17.01	13.19	7.98	7.95
Long-Term Debt	18.9	0	0	0	0
Other Long-Term Liabilities	15.48	12.3	17.15	16.19	1.02
Total Long-Term Liabilities	34.38	12.3	17.15	16.19	1.02
Total Liabilities	51.1	29.3	30.34	24.16	8.97
Total Debt	18.9	0	0	1.29	0
Retained Earnings	-660.82	-637.16	-605.64	-570.5	-523.91
Comprehensive Income	-1.2	-0.7	1.95	0.59	-2.73
Shareholders' Equity	24.17	44.57	84.5	81.54	73
Net Cash / Debt	11.87	51.34	48.57	65.08	54.25
Net Cash / Debt Growth	-76.87%	5.69%	-25.37%	19.97%	-35.13%
Net Cash Per Share	0.89	3.76	3.57	5.89	5.65
Working Capital	42.62	56.42	48.78	66.05	56.78
Book Value Per Share	1.81	3.27	6.21	7.38	7.61

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).